麻豆传媒

FDA approves tapinarof cream 1% for adults and kids 2 years and up

Study details frequent sleep loss, sleep medication use in pediatric atopic dermatitis families

Nemolizumab indicated for chronic skin disease in adults and kids ages 12 years and up

EASI-75 was achieved by majority of patients taking 15 mg or 30 mg at 76 weeks

38% of patients treated with IL-13 blocker achieved clear or almost-clear skin at 16 weeks

More patients see treatment success with delgocitinib vs cream vehicle in two phase III trials

Over 90 days of exposure linked to adverse events

At highest dose, novel cendakimab hits primary endpoint in phase II study

Further study needed to explore link between skin sodium and autoimmune inflammatory conditions

An increased number of antibiotic courses corresponded to a dose-response-like increased risk

Association primarily limited to children with neurodevelopmental comorbidities

Urticaria severity reduced within weeks of treatment

No link between prenatal exposure and risk for autoimmune conditions, however

Our panel of experts discuss when might be the right time to reduce therapy